Skip to main content
lakatos laszlo - colon gastroenterologia


1 Molinié F, Gower-Rousseau C, Yzet T, et al. Opposite evolution in incidence of Crohn’s disease and ulcerative colitis
in Northern France (1988-1999). Gut 2004;53:843-848.
2 Card T, Logan RFA, Rodrigues LC, Wheeler JG. Antibioticum use and the developement of Crohn’s disease. Gut
3 Manguso F, Sanges M, Staiano T. Cigarette smoking and appendectomy are risk factors for extraintestinal
manifestations in ulcerative colitis. Am J Gastroenterol 2004,99:328-334.
4 Masala G, Bagnoli S, Ceroti M et al. Divergent patterns of total and cancer mortality in ulcerative colitis and Crohn’s
disease patients: the Florence IBD study 1978-2001. Gut 2004;53:1309-1313.
5 Franchimont D, Vermeire S, Housni HEI, et al. Deficient hos-bacteria interactions in inflammatory bowel disease?
Toll-like receptor (TLR)-4, Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitis. Gut
6 Kugathasan S, Collins N, Maresso K, et al. CARD15 gene mutations and risk for early surgery in pediatric-onset
Crohn’s disease. Clin Gastroenterol Hepatol 2004;2:1003-1009.
7 Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of colonic mucosa associated bacterial microflora in
patients with active inflammatory bowel disease, Gut 2004;53: 685-693.
8 Martin HM, Campbell BJ, Hart CA, et al. Enhanced Escherichia coli adherence and invasion in Crohn’s disease and
colon cancer. Gastroenterology 2004;127:80-93.
9 Naser SA, Ghobrial G, Rornero C, Valentine JF. Culture of Mycobacterium avium subspecies paratuberculosis from
the blood of patients with Crohn’s disease. Lancet 2004;364:1038-1044.
10 Aisenberg J, Legfnani PE, Nilubol N, ..D. Sachar. Are pANCA, ASA, or cytokine gene polymorphisms associated
with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am J Gastroenterol 2004;99:432-441.
*Cosnes J, Nion-Larmurier I, Afchain P, et al. Gender differences in the response of colitis to smoking. Clin
Gastroenterol Hepatol 2004;41-48.
12 Florin THJ, Pandeya N, Radford-Smith GI. Epidemiology of appendicectomy in primary sclerosing cholangitis and
ulcerative colitis: its influence on the clinical behaviour of the diseases. Gut 2004;53:973-979.
13 Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor
for thromboembolism? Gut 2004;53:542-548.
14 Solem CA, Loftus EV, Tremaine WJ, Sandborne WJ. Venous thromboembolism in inflammatory bowel disease. Am J
Gastroenterol 2004;97-101.
15 Munk EM, Pedersen L, Floyd A, et al. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine
treatment and risk of acute pancreatitis: a population-based case-control study. Am J Gastroenterol 2004;99:884-888.
16 Lewis JD, Aberra FN, Lichtenstein GR, et al. Seasonal variation in flares of inflammatory bowel disease.
Gastroenterology 2004;126:665-673.
17 *Jowett SL, Seal CJ, Pearce MS, et al. Influence of dietary factors on the clinical course of ulcerative colitis: a
prospective cohort study. Gut 2004;53:1479-1484.
18 *Tilg H, Kaser A. Diet and relapsing ulcerative colitis: take of the meat? Gut 2004;53:1399-1401.
19 Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is
associated with increased risk for early surgery In Crohn’s disease. Gut 2004;53:1117-1122.
20 Winther KV, Jess T, Langholz E, et al. Long-therm risk on cancer in ulcerative colitis: a population-based cohort study
from Copenhagen county. Clin Gastroentero Hepatol 2004;2:1088-1095.
21 Lobel EZ, Korelitz BI, Xuereb MA, Panagopoulos G. A search for the optimal duration of treatment with 6-
mercaptopurine for ulcerative colitis. Am J Gastroemterol 2004;99:462-465.
22 Hanauer SB, Strömberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind,
placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2:379-388.
23 Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine
monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative
colitis. Am J Gastroenterol 2004;99:1122-1128.
24 Cuffari C, Dassopoulos T, Turnbough L, et al. Thiopurin methyltransferase activity influences clinical response to
azathiopurine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004;2:410-417.
25 Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn’s disease remission with 6-
mercaptopurine, mesalamine, and placebo: a 2-year trial. Gastroenterology 2004;127:723-729.
26 Moskowitz DN, Bodian C, Chapman ML, Marion JF, et al. The effect on the fetus of medications used to treat
pregnant inflammatory bowel disease patients, Am J Gastroenterol 2004;99:656-660.
27 Van Staa TP, Travis S, Leufkens HGM, Logan RF. 5-aminosalicylic acids and the risk of renal disease. A large british
epidemiologic study. Gastroenterology 2004;126:1733-1739.
28 Sands BE, Anderson FH, Bernsteint CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl
J Med 2004;350:876-885.
29 Sandborn, WJ, Feagan BG, Radford-Smith G, et al. CDP-571, a humanised monoclonal antobody to tumour necrosis
factor α, for moderate to severe Crohn’s disease: a randomised, dfouble blind, placebo controlled trial. Gut
30 Sandborn WJ, Hanauer SB, Loftus EV, et al. An open-label study of the human anti-TNF monoclonal antobody
adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol
31 Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med
32 Parsi M, Lashner BA, Achkar JP, et al. Type of fistula determinates pesponse to infliximab in patients with fistulous
Crohn’s disease. Am J Gastroenterol 2004;99:445-449.
33 Sands BE, Blank MA, Patel K et al. Long-term treatmwent of rectovaginal fistulas in Crohn’s disease: response to
infliximab in the ACCENT II study. Clin Gastroenterol Hepatol 2004;2:912-920.
34 Rasul I, Wilson SR, MacRaeH, Greenberg GR. Clinical and radiological responses after infliximab treatment for
perianal fistulizing Crohn’s disease. Am J. Gastroenterol 2004;99:82-88.
35 *Colombel JF, Loftus EV, Tremaine WJ, et al. Early postoperative complications are not increased in patients with
Crohn’s disease treated preoperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004;99:878-
36 Ljung T, Karlén P, Schmidt PM, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population
based cohort from Stockholm county. Gut 2004;53:849-853.
37 Burgmann T, Rawsthorne P, Bernstein CN. Predictors of alternative and complemenary medicine use in inflammatory
bowel disease: do measures of coventional health care utilization relate to use. Am J Gastroenterol 2004;99:889-893.
38 Mimura T, Rizzello F, Hellwig U, et al. Once high dose probiotic therapy (VSL#3) for maintaining remission in
recurrent or refractory pouchitis. Gut 2004;53:108-114.
39 Yang YX, Henessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients.
Gastoenterology 2004;127:1044-1050.
40 Hendricks YMC, Wagner A, Morreau H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6
mutations: impact on counseling and surveillance.
41 Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in
postmenopausal women. N Engl J Med 2004;350:991-1004.
42 Cho E, Smith-Warner SA, Ritz J, et al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies.
Ann Int Med 2004;140:603-603.
43 Anderson JC, Attam R, Alpern Z, et al. Prevalence of colorectal neoplasia in smokers. Am J Gastroenterol
44 Larsson SC, Bergkvist L, Wolk A. Magnesium intake in relation to risk of colorectal cancer in women. JAMA
45 Chao A, Thun MJ, Connell CJ,. et al. Meat consumption and risk of colorectal cancer. JAMA 2005;293:171-182.
46 Erlinger TP, Platz EA, Rifai N, Helzlsouner KJ. C-reactive protein and the risk of colorectal cancer. JAMA
47 Chan AT, Giovanucci EL, Schernhammer ES, et al. A prospective study of aspirin use and the risk for colorectal
adenoma. Ann Int Med 2004;140:157-166.
48 Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood cor colorectal-cancer screening
in an average-risk population. N Engl J Med 2004;351:2704-2714.
49 Brand RE, Ross mE, Shuber AP. Reproducibility of a multitarget stool-based DNA assay for colorectal cancer
detection. Am J Gastroenterol 2004;99:1338-1341.
50 Müller HM, Oberwalder M, Fiegl H, et al. Methylation changes in faecal DNA: a marker for colorectal cancer
screening. Lancet 2004;363:1283-1285.
51 Farraye FA, Wong M, Hurwitz S, et al. Barriers to endoscopic colorectal cancer screening: are women different from
men? Am J Gastroenterol 2004;99:341-349.
52 Sheikh RA, Kapre S, Calof OM, et al. Screening preferences for colorectal ancer: a patient demografic study. Southern
Med Ass 2004;97:224-230.
53 Murray CDR, Flynn J, Ratcliffe L, et al. Effect of acute physical and psychological stress on gbut autonom
innervation in irritable bowel syndrome. Gatroenterology 2004;127:1695-1703.
54 Gwee KA, Wee SW, Wong ML et al. The prealence, symptom characteristics, and impact of irritable bowel syndrome
in an Asian urban community. Am J Gastroenterol 2004;99:924-931.
55 Howell S, Talley NJ, Quine S, Poulton R. The irritable bowel syndrome has origins in childhood socioeconomic
environment. Am J Gastroenterol 2005;99:1572-1578.
56 Okhuysen PC, Jiang ZD, Carlin L, et al. Post-Diarrhea chronic intestinal symptoms in North American trevelers to
Mexico. Am J Gastroenterol 2005;99:1774-1778.
57 Mearin F, Baró E, Roset M, et al. Clinical patterns over time in irritable bowel syndrome: symptom instability and
severity variability. Am J Gastroenterol 2004;99:113-121.
58 Miller V, Hopkins L, Whorwell PJ. Suicidal ideation inpatients with irritable bowel syndroma. Clin Gastroenterol
Hepatol 2004;2:1064-1068.
59 Longstreth G, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology
60 Lembo AJ, Olden KW, Ameen WZ, et al. Effect of alosetron on bowel urgency and global symptoms in women with
severe, diarrhea-predominant irritable bowel syndrome: analisis of two controlled trials. Clin Gastroenterol Hepatol
61 Johal SS, Hammond J, Solomon K, et al. Clostridium difficile associated diarrhoea in hospitalised patients: onset in
the community and hospital and role of flexible sigmoidoscopy. Gut 2004;53:673-677.
62 Cappel MS. Colonic toxicity of administered drugs and chemicals. Am J Gastroenterol 2004;99:1175-1190.
63 Higgins PDR, Juhanson JF. Epidemiology of constipation in North America: a systemic review. Am J Gastroenterol
64 Johanson JF, Wald A, Tougas G, et al. Effect of tegaserod in chronic constipation: a randomized double-blind,
controlled trial.Clin Gastroenterol Hepatol 2004;2:796-805
65 West J, Logan RFA, Smith CJ, et al. Malignancy and mortality in people with coeliac disease: population based cohort
study. BMJ 2004;329:716-718.
66 Olesen M, Eriksson S, Bohr J, et al. Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. Gut